Advertisement
Screener

ENANTA PHARMACEUTICALS, INC (ENTA) Operating Leases, Rent Expense

1.6 / 5 stars · 38/120 Roast Me

ENANTA PHARMACEUTICALS, INC Operating Leases, Rent Expense

ENANTA PHARMACEUTICALS, INC (ENTA) reported Operating Leases, Rent Expense of $2.49 million for the 12-month period ending 2019-09-30, per its 10-K filed 2019-11-27.

Discontinued › Expense Statement › Operating Expenses

us-gaap:LeaseAndRentalExpense · last filed 2019-11-27

  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2019-09-30 was $623.00K, a 21.21% increase year-over-year.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2019-06-30 was $623.00K, a 23.12% increase year-over-year.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2019-03-31 was $623.00K, a 22.88% increase year-over-year.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2018-12-31 was $623.00K, a 23.12% increase year-over-year.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2019 was $2.49M, a 22.58% increase from fiscal 2018.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2018 was $2.03M, a 0.40% increase from fiscal 2017.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2017 was $2.02M, a 0.00% change from fiscal 2016.
  • ENANTA PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2016 was $2.02M, a 52.71% increase from fiscal 2015.
Period endOperating Leases, Rent Expense 3 monthOperating Leases, Rent Expense 6 monthOperating Leases, Rent Expense 9 monthOperating Leases, Rent Expense 12 month
2019-09-30$623.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
$1.25M
derived: sum of 2 quarters · filed 2019-11-27
$1.87M
derived: sum of 3 quarters · filed 2019-11-27
$2.49M
10-K · filed 2019-11-27
2019-06-30$623.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09
$1.25M
derived: sum of 2 quarters · filed 2019-08-09
$1.87M
10-Q · filed 2019-08-09
$2.38M
derived: sum of 4 quarters · filed 2019-11-27
2019-03-31$623.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10
$1.25M
10-Q · filed 2019-05-10
$1.76M
derived: sum of 3 quarters · filed 2019-11-27
$2.27M
derived: sum of 4 quarters · filed 2019-11-27
2018-12-31$623.00K
10-Q · filed 2019-02-08
$1.14M
derived: sum of 2 quarters · filed 2019-11-27
$1.64M
derived: sum of 3 quarters · filed 2019-11-27
$2.15M
derived: sum of 4 quarters · filed 2019-11-27
2018-09-30$514.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
$1.02M
derived: sum of 2 quarters · filed 2019-11-27
$1.53M
derived: sum of 3 quarters · filed 2019-11-27
$2.03M
10-K · filed 2019-11-27
2018-06-30$506.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09
$1.01M
derived: sum of 2 quarters · filed 2019-08-09
$1.52M
10-Q · filed 2019-08-09
$2.02M
derived: sum of 4 quarters · filed 2019-11-27
2018-03-31$507.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10
$1.01M
10-Q · filed 2019-05-10
$1.52M
derived: sum of 3 quarters · filed 2019-11-27
$2.02M
derived: sum of 4 quarters · filed 2019-11-27
2017-12-31$506.00K
10-Q · filed 2019-02-08
$1.01M
derived: sum of 2 quarters · filed 2019-11-27
$1.52M
derived: sum of 3 quarters · filed 2019-11-27
$2.02M
derived: sum of 4 quarters · filed 2019-11-27
2017-09-30$506.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27
$1.01M
derived: sum of 2 quarters · filed 2019-11-27
$1.52M
derived: sum of 3 quarters · filed 2019-11-27
$2.02M
10-K · filed 2019-11-27
2017-06-30$506.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09
$1.01M
derived: sum of 2 quarters · filed 2018-08-09
$1.52M
10-Q · filed 2018-08-09
$2.02M
derived: sum of 4 quarters · filed 2018-11-29
2017-03-31$507.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10
$1.01M
10-Q · filed 2018-05-10
$1.52M
derived: sum of 3 quarters · filed 2018-11-29
$2.02M
derived: sum of 4 quarters · filed 2018-11-29
2016-12-31$506.00K
10-Q · filed 2018-02-09
$1.01M
derived: sum of 2 quarters · filed 2018-11-29
$1.52M
derived: sum of 3 quarters · filed 2018-11-29
$2.02M
derived: sum of 4 quarters · filed 2018-11-29
2016-09-30$506.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29
$1.01M
derived: sum of 2 quarters · filed 2018-11-29
$1.52M
derived: sum of 3 quarters · filed 2018-11-29
$2.02M
10-K · filed 2018-11-29
2016-06-30$506.00K
10-Q · filed 2016-08-09
$1.01M
derived: sum of 2 quarters · filed 2016-08-09
$1.52M
10-Q · filed 2017-08-09
$2.02M
derived: sum of 4 quarters · filed 2017-12-11
2016-03-31$507.00K
10-Q · filed 2016-05-10
$1.01M
10-Q · filed 2017-05-10
$1.52M
derived: sum of 3 quarters · filed 2017-12-11
$1.86M
derived: sum of 4 quarters · filed 2017-12-11
2015-12-31$506.00K
10-Q · filed 2017-02-09
$1.01M
derived: sum of 2 quarters · filed 2017-12-11
$1.35M
derived: sum of 3 quarters · filed 2017-12-11
$1.59M
derived: sum of 4 quarters · filed 2017-12-11
2015-09-30$505.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-11
$846.00K
derived: sum of 2 quarters · filed 2017-12-11
$1.09M
derived: sum of 3 quarters · filed 2017-12-11
$1.33M
10-K · filed 2017-12-11
2015-06-30$341.00K
10-Q · filed 2016-08-09
$584.00K
derived: sum of 2 quarters · filed 2016-08-09
$821.00K
10-Q · filed 2016-08-09
$1.06M
derived: sum of 4 quarters · filed 2016-12-09
2015-03-31$243.00K
10-Q · filed 2016-05-10
$480.00K
10-Q · filed 2016-05-10
$717.00K
derived: sum of 3 quarters · filed 2016-12-09
$954.00K
derived: sum of 4 quarters · filed 2016-12-09
2014-12-31$237.00K
10-Q · filed 2016-02-09
$474.00K
derived: sum of 2 quarters · filed 2016-12-09
$711.00K
derived: sum of 3 quarters · filed 2016-12-09
$948.00K
derived: sum of 4 quarters · filed 2016-12-09
2014-09-30$237.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-09
$474.00K
derived: sum of 2 quarters · filed 2016-12-09
$711.00K
derived: sum of 3 quarters · filed 2016-12-09
$948.00K
10-K · filed 2016-12-09
2014-06-30$237.00K
10-Q · filed 2015-08-10
$474.00K
derived: sum of 2 quarters · filed 2015-08-10
$711.00K
10-Q · filed 2015-08-10
$948.00K
derived: sum of 4 quarters · filed 2015-12-11
2014-03-31$237.00K
10-Q · filed 2015-05-08
$474.00K
10-Q · filed 2015-05-08
$711.00K
derived: sum of 3 quarters · filed 2015-12-11
$948.00K
derived: sum of 4 quarters · filed 2015-12-11
2013-12-31$237.00K
10-Q · filed 2015-02-06
$474.00K
derived: sum of 2 quarters · filed 2015-12-11
$711.00K
derived: sum of 3 quarters · filed 2015-12-11
$948.00K
derived: sum of 4 quarters · filed 2015-12-11
2013-09-30$237.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-11
$474.00K
derived: sum of 2 quarters · filed 2015-12-11
$711.00K
derived: sum of 3 quarters · filed 2015-12-11
$948.00K
10-K · filed 2015-12-11
2013-06-30$237.00K
10-Q · filed 2014-08-12
$474.00K
derived: sum of 2 quarters · filed 2014-08-12
$711.00K
10-Q · filed 2014-08-12
$948.00K
derived: sum of 4 quarters · filed 2014-12-11
2013-03-31$237.00K
10-Q · filed 2014-05-12
$474.00K
10-Q · filed 2014-05-12
$711.00K
derived: sum of 3 quarters · filed 2014-12-11
$948.00K
derived: sum of 4 quarters · filed 2014-12-11
2012-12-31$237.00K
10-Q · filed 2014-02-13
$474.00K
derived: sum of 2 quarters · filed 2014-12-11
$711.00K
derived: sum of 3 quarters · filed 2014-12-11
$948.00K
derived: sum of 4 quarters · filed 2014-12-11
2012-09-30$237.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-11
$474.00K
derived: sum of 2 quarters · filed 2014-12-11
$711.00K
derived: sum of 3 quarters · filed 2014-12-11
$948.00K
10-K · filed 2014-12-11
2012-06-30$237.00K
10-Q · filed 2013-08-12
$474.00K
derived: sum of 2 quarters · filed 2013-08-12
$711.00K
10-Q · filed 2013-08-12
2012-03-31$237.00K
10-Q · filed 2013-05-15
$474.00K
10-Q · filed 2013-05-15
2011-09-30$2.00M
10-K · filed 2013-12-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Emergent BioSolutions Inc. (EBS)United States$0.347B-2.43
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
Rezolute, Inc. (RZLT)United States$0.382B-6.45
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63